Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience

Seminars in Hematology

Volumn 38, Issue 3, 2001, Pages 209-218

  Sirohi, Bhawna ^a   Kulkarni, Samar ^a   Powles, Ray ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; AGED; AUTOTRANSPLANTATION; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; EXPERIENCE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 0034894227     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90012-5     Document Type: Article

References (48)

1. Prednisone pulse therapy for refractory myeloma
2. Total therapy with tandem transplants for newly diagnosed multiple myeloma
3. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
4. Autologous stem cell transplantation in multiple myeloma: Results of the European Group for Bone Marrow Transplantation
5. Detection of circulating tumour cells in multiple myeloma by a PCR-based method
6. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results
7. High-dose melphalan for multiple myeloma: Long-term follow-up data
8. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
9. A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma
10. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma inferior compared to historical controls receiving tandem transplants with melphalan alone
11. DCEP consolidation chemotherapy (CC) after 2 cycles of melphalan-based high dose therapy (HDT) - High incidence of CR and superior outcome in comparison with matched historical controls
12. Thiotepa, bulsulfan and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high risk myeloma
13. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients
14. Infused vincristine and Adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients
15. The use of verapamil to overcome drug resistance in myeloma
16. Intensive treatment for multiple myeloma and criteria for complete remission
17. Pharmacokinetics of high-dose melphalan in adults: Influence of renal function
18. Impact of previous high dose therapy on outcome after allografting for multiple myeloma
19. Evidence that multiple myeloma may be regulated by homostatic control mechanisms: Correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response
20. Maintenance treatment with recombinant alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy
21. High-dose busulphan in patients with myeloma
22. High dose intravenous melphalan for plasma cell leukaemia and myeloma
23. In vitro studies of ways to overcome drug resistance to VAMP-high-dose melphalan in the treatment of multiple myeloma
24. Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM)
25. 2 melphalan without hematopoietic stem cell or growth factor support as initial therapy
26. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - A phase I/II feasibility and tolerance study of 17 patients
27. Collection of peripheral blood stem cells in newly-diagnosed myeloma patients without any prior cytoreductive therapy
28. Continued first complete remission in multiple myeloma for over 10 years: A series of "operationally cured" patients
29. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment
30. Maintenance therapy for remission in myeloma with Intron A following high dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue
31. Early response to infusional chemotherapy is an independent prognostic factor in newly-diagnosed IgG and IgA multiple myeloma
32. Comparison of marrow vs. blood-derived stem cells for autografting in previously untreated multiple myeloma
33. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophophamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma
34. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
35. Multiple myeloma treated with high dose intravenous melphalan
36. Marked anti-rumour effect from anti-angiogenesis therapy with thalidomide in high risk refractory multiple myeloma
37. Kinetics of paraprotein clearance after autografting for multiple myeloma
38. 2): High incidence of atrial fibrillation and treatment-related mortality
39. A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma
40. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system
41. The implications of compromised renal function at the time of presentation: A single centre study of 251 patients
42. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
43. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Childrens Cancer Group
44. Immunotherapeutic strategies for the treatment of plasma cell malignancies
45. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study
46. Peripheral blood stem cell transplantation for multiple myeloma: Identification of favourable variables for rapid engraftment in 225 patients
47. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
48. A meta-analysis of trials of interferon as therapy for myeloma